{"id":"W2591046956","doi":"10.1634/theoncologist.2016-0265","title":"Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"U.S. Food and Drug Administration; Eli Lilly and Company","keywords":"Medicine; Ramucirumab; Capecitabine; Internal medicine; Hazard ratio; Gastroenterology; Adverse effect; Clinical endpoint; Phases of clinical research; Cancer; Randomized controlled trial; Confidence interval; Oncology; Chemotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001471447,0.0002647377,0.001320674,0.0001914967,0.0002013564,0.00003314929,0.0004341512,0.00005648376,0.0003367552],"category_scores_gemma":[0.0007681215,0.0001155826,0.00004146208,0.0004528445,0.0007527992,0.0001658208,0.0001205483,0.0003701422,0.000002547228],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00081221,"about_ca_system_score_gemma":0.001002935,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.009233505,"about_ca_topic_score_gemma":0.06360273,"domain_scores_codex":[0.9972031,0.0006121263,0.0006484535,0.0003877431,0.0007251718,0.0004234215],"domain_scores_gemma":[0.9976081,0.0004310566,0.0005529641,0.0008567636,0.0004485953,0.0001025267],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.847567,0.01522173,0.0712094,0.0001468837,0.0003059817,0.0002569032,0.002462033,0.0002111442,0.00003276358,0.000008308796,0.00005916362,0.06251866],"study_design_scores_gemma":[0.8242627,0.03221455,0.1403385,0.0008267986,0.0003355752,0.00001655089,0.001079625,0.0006211613,0.00008850764,0.000009453064,0.00003643629,0.0001701138],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889151,0.00007089614,0.00002203476,0.001095906,0.00004360036,0.009430049,0.00003778002,0.00002541566,0.0003591485],"genre_scores_gemma":[0.9970621,0.00008245041,0.0001917395,0.00006235221,0.00001593547,0.001556316,0.00002182093,0.00003963675,0.0009676574],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06912906,"threshold_uncertainty_score":0.9973641,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05173664560861214,"score_gpt":0.408330866346466,"score_spread":0.3565942207378539,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}